HECTD2 and hepatocellular carcinoma: More importantly, using patient‐derived xenograft models and DEN/CCl4 induced HCC models, we demonstrated that nanoparticles (NPs) targeting HECTD2 may provide a novel therapeutic approach to mitigating lenvatinib resistance in HCC.